Nuveen LLC Buys Shares of 168,420 Ventyx Biosciences, Inc. $VTYX

Key Points

• Nuveen LLC has made a new investment in Ventyx Biosciences, Inc., purchasing 168,420 shares valued at approximately $194,000, representing a 0.24% ownership stake.
• Ventyx recently reported quarterly earnings of ($0.38) per share, which surpassed analysts' expectations of ($0.45).
• Following a rating adjustment, Wall Street has changed Ventyx Biosciences' rating from "sell" to "hold." The consensus target price for the stock is set at $7.50.

Nuveen LLC bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 168,420 shares of the company's stock, valued at approximately $194,000. Nuveen LLC owned 0.24% of Ventyx Biosciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in VTYX. Monaco Asset Management SAM grew its stake in Ventyx Biosciences by 372.7% in the 1st quarter. Monaco Asset Management SAM now owns 1,134,444 shares of the company's stock valued at $1,305,000 after acquiring an additional 894,444 shares during the period. Cutter & CO Brokerage Inc. purchased a new position in Ventyx Biosciences during the first quarter valued at $62,000. CWM LLC grew its position in shares of Ventyx Biosciences by 1,733.8% in the first quarter. CWM LLC now owns 53,088 shares of the company's stock valued at $61,000 after purchasing an additional 50,193 shares during the period. Cerity Partners LLC acquired a new stake in shares of Ventyx Biosciences in the first quarter valued at about $56,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Ventyx Biosciences during the first quarter worth about $28,000. Hedge funds and other institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Stock Performance

Shares of NASDAQ VTYX traded up $0.01 during mid-day trading on Thursday, reaching $2.38. The company's stock had a trading volume of 285,066 shares, compared to its average volume of 429,934. The stock has a 50-day moving average of $2.68 and a two-hundred day moving average of $1.94. The stock has a market capitalization of $169.72 million, a P/E ratio of -1.42 and a beta of 0.95. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.07. Analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Ventyx Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.